41.67 USD
+0.68 (+1.66%)
41.67 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to KNSA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 55.08. This target is 32.18% above the current price.
KNSA was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about KNSA.
In the previous month the buy percentage consensus was at a similar level.
KNSA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-29 | TD Cowen | Initiate | Buy |
| 2025-09-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-09-13 | Jefferies | Initiate | Buy |
| 2024-07-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-03 | Wells Fargo | Initiate | Overweight |
| 2024-05-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-01-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-03-09 | JP Morgan | Maintains | Overweight |
| 2021-12-29 | B of A Securities | Maintains | Buy |
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
What do analysts expect the price target to be for KINIKSA PHARMACEUTICALS INTE (KNSA)?
13 analysts have analysed KNSA and the average price target is 55.08 USD. This implies a price increase of 32.18% is expected in the next year compared to the current price of 41.67.
What is the consensus rating for KNSA stock?
The consensus rating for KINIKSA PHARMACEUTICALS INTE (KNSA) is 86.1538 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
The number of analysts covering KINIKSA PHARMACEUTICALS INTE (KNSA) is 13.